Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Lucid Diagnostics Inc (LUCD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: LUCD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $3.79
Year Target Price $3.79
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 126.59M USD | Price to earnings Ratio - | 1Y Target Price 3.79 |
Price to earnings Ratio - | 1Y Target Price 3.79 | ||
Volume (30-day avg) - | Beta 1.32 | 52 Weeks Range 0.72 - 1.80 | Updated Date 06/29/2025 |
52 Weeks Range 0.72 - 1.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1508.09% |
Management Effectiveness
Return on Assets (TTM) -92.04% | Return on Equity (TTM) -1897.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188874798 | Price to Sales(TTM) 30.34 |
Enterprise Value 188874798 | Price to Sales(TTM) 30.34 | ||
Enterprise Value to Revenue 45.26 | Enterprise Value to EBITDA -0.67 | Shares Outstanding 108195000 | Shares Floating 66661856 |
Shares Outstanding 108195000 | Shares Floating 66661856 | ||
Percent Insiders 34.54 | Percent Institutions 9.78 |
Analyst Ratings
Rating 4.67 | Target Price 3.79 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lucid Diagnostics Inc
Company Overview
History and Background
Lucid Diagnostics Inc. was incorporated in 2018 and focuses on medical diagnostic testing for esophageal diseases, particularly Barrett's esophagus and esophageal cancer. It aims to improve early detection and prevention.
Core Business Areas
- EsoGuardu00ae Esophageal DNA Test: A non-endoscopic diagnostic test designed to detect esophageal precancer and cancer biomarkers in samples collected using the EsoChecku00ae device.
- EsoChecku00ae Cell Collection Device: A device used to collect esophageal cells during a quick and painless office procedure, which is then used for the EsoGuard test.
- Research and Development: Continuously innovating and improving diagnostic tools for early detection and management of esophageal diseases.
Leadership and Structure
The leadership team comprises experienced professionals in diagnostics, healthcare, and biotechnology. The company has a structured management team responsible for R&D, commercialization, and operations, overseen by a Board of Directors.
Top Products and Market Share
Key Offerings
- EsoGuardu00ae Esophageal DNA Test: This test detects DNA biomarkers associated with Barrett's esophagus and esophageal cancer. It is a non-endoscopic alternative to traditional endoscopy. Revenue data is still developing as the company grows adoption. The primary competitor is traditional endoscopy and biopsy performed by gastroenterologists.
- EsoChecku00ae Cell Collection Device: A device that facilitates non-endoscopic sample collection for EsoGuard testing. This device is crucial to the company's business model. Competitors are other methods of sample collection during traditional endoscopy.
Market Dynamics
Industry Overview
The industry focuses on early cancer detection and preventative healthcare. The market includes companies offering diagnostic tools and services for gastrointestinal diseases.
Positioning
Lucid Diagnostics is positioned as a leader in non-endoscopic esophageal cancer screening. Its competitive advantage lies in the non-invasive nature of its EsoGuard and EsoCheck technology. It offers a simpler and more patient-friendly way of esophageal monitoring.
Total Addressable Market (TAM)
The estimated TAM for esophageal cancer diagnostics is several billion dollars, considering the prevalence of GERD and Barrett's esophagus. Lucid is well-positioned to capture a significant share through its innovative screening methods.
Upturn SWOT Analysis
Strengths
- Innovative non-endoscopic technology (EsoGuard & EsoCheck)
- Potential for early cancer detection
- Reduced invasiveness compared to traditional endoscopy
- Strong intellectual property portfolio
- Addressing a significant unmet clinical need
Weaknesses
- Limited market penetration and adoption
- Reliance on reimbursement from payers (insurance companies)
- Cash burn and need for continued funding
- Competition from established endoscopic procedures
Opportunities
- Expanding clinical validation and acceptance
- Securing favorable reimbursement policies
- Partnerships with gastroenterology practices and healthcare systems
- Expanding into international markets
- Development of additional diagnostic applications
Threats
- Competition from established diagnostic methods
- Unfavorable changes in reimbursement policies
- Slower than expected market adoption
- Regulatory hurdles and compliance requirements
- Risk of technological obsolescence
Competitors and Market Share
Key Competitors
- MDGN
- CGDX
- Exact Sciences (EXAS)
Competitive Landscape
Lucid Diagnostics holds a competitive advantage through its non-invasive technology. Its main disadvantage is its size and resources relative to larger, more established diagnostic companies. The market is dominated by companies offering diagnostic tools and services.
Growth Trajectory and Initiatives
Historical Growth: Lucid has shown growth in revenue as they expand their commercial operations and secure more partnerships.
Future Projections: Future growth depends on increased adoption of EsoGuard, favorable reimbursement coverage, and successful marketing efforts. Analyst expectations are for continued revenue growth but will need to see improvements on margins to reach break-even points.
Recent Initiatives: Recent initiatives include expanding sales and marketing, conducting clinical trials to demonstrate efficacy, securing insurance coverage, and partnerships with health systems.
Summary
Lucid Diagnostics is an emerging company focused on early cancer detection using innovative non-endoscopic technology. Its strength lies in its unique approach, but it faces challenges related to market adoption, reimbursement, and competition. Strong growth potential remains, but profitability has yet to be seen and financial health must be watched. Lucid Diagnostics must increase adoption by focusing on positive clinical results, improving reimbursement coverage, and establishing further strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lucid Diagnostics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-10-14 | Chairman & CEO Dr. Lishan Aklog M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 72 | Website https://www.luciddx.com |
Full time employees 72 | Website https://www.luciddx.com | ||
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.